Palestine Media Agency – Pmedia – A recent medical study by the prestigious Mayo Clinic revealed promising effects of GLP-1 class weight loss drugs on heart health in patients suffering from severe obesity and left ventricular heart failure. The research, focusing on drugs such as semaglutide and tirzepatide, showed significant improvements in heart structure and pumping function after one year of treatment.
Notably, the cardiac benefits remained even after accounting for weight loss, indicating the drugs’ direct therapeutic effects on heart tissue. Extended analyses over two years further confirmed sustained improvement in left ventricular ejection fraction.
Parallel reports presented at the American Heart Association highlighted semaglutide's positive impact on heart pressure and reduction of heart failure symptoms in obese patients. These findings are part of a global research wave investigating novel obesity treatments to address chronic illnesses, aiming to reduce hospitalizations and improve patients’ quality of life.
Researchers emphasize the need for further studies to establish precise treatment protocols and hope these medications will become integral in cardiovascular disease management. The results offer new hope in combating the obesity epidemic and its severe cardiac consequences, which may lead to updating global medical guidelines in the near future.

